<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0025517" disease_type="Disease or Syndrome" abbrv="">Metabolic diseases</z:e> are associated with activation of the innate immune system in various tissues and characterised by elevated inflammatory factors and the presence of immune cells </plain></SENT>
<SENT sid="1" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> develops when islet beta-cells are deficient in producing sufficient insulin to overcome peripheral <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Intra-islet IL-1β activity diminishes beta-cell function and survival and governs islet <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Targeting the IL-1 system with the IL-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> IL1Ra improved insulin secretion, glycemia and reduced systemic <z:mp ids='MP_0001845'>inflammation</z:mp> in a proof of concept study with patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Currently, long lasting and specific IL-1β blocking antibodies are evaluated in clinical trials and this may lead to a novel cytokine-based treatment for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>. © 2012 The Authors </plain></SENT>
<SENT sid="5" pm="."><plain>British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society </plain></SENT>
</text></document>